BioPharma and CRO organizations are under immense pressure to develop novel disease treatments while ensuring they are safe, effective, and affordable. Rapidly changing technologies, increased clinical study complexities, and escalating regulatory scrutiny are driving higher development costs and prolonging treatment delivery.